ABC transporters and cytochromes P450 in the human central nervous system: Influence on brain pharmacokinetics and contribution to neurodegenerative disorders

Expert Opinion on Drug Metabolism and Toxicology

Volumn 6, Issue 10, 2010, Pages 1161-1174

  Dutheil, Fabien ^a,b   Jacob, Aude ^a,c   Dauchy, Sandrine ^a,c   Beaune, Philippe ^a,b,e   Scherrmann, Jean Michel ^a,c   Declves, Xavier ^a,c,d   Loriot, Marie Anne ^a,b,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c CNRS   (France)

^d Service de Pharmacie   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

ATP binding cassette transporters; CYP enzymes; Human brain; Neurodegenerative diseases; Xenobiotics

Indexed keywords

ABC TRANSPORTER; ANALGESIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450; CYTOCHROME P450 1B1; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 2J2; DIELDRIN; MONOAMINE OXIDASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PESTICIDE; TRICYCLIC ANTIDEPRESSANT AGENT; VASODILATOR AGENT;

ALZHEIMER DISEASE; BRAIN; BRAIN BLOOD VESSEL; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC SUSCEPTIBILITY; HUMAN; MICROVASCULATURE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BLOOD-BRAIN BARRIER; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DELIVERY SYSTEMS; HUMANS; NEURODEGENERATIVE DISEASES; XENOBIOTICS;

EID: 77956800050     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2010.510832     Document Type: Review

References (98)

1. Guengerich FP, Okazaki O, Seto Y, et al. Radical cation intermediates in N-dealkylation reactions. Xenobiotica 1995;25:689-709
2. Dutheil F, Dauchy S, Diry M, et al. Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab Dispos 2009;37:1528-1538
3. Dauchy S, Dutheil F, Weaver RJ, et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 2008;107:1518-1528
4. Miksys S, Tyndale RF. Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition. Neuropsychopharmacology 2009;34:634-640
5. Hiroi T, Kishimoto W, Chow T, et al. Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology 2001;142:3901-3908
6. Elbaz A, Levecque C, Clavel J, et al. CYP2D6 polymorphism, pesticide exposure, and Parkinsons disease. Ann Neurol 2004;55:430-434
7. Seliskar M, Rozman D. Mammalian cytochromes P450 - importance of tissue specificity. Biochim Biophys Acta 2007;1770:458-466
8. Michels R, Marzuk PM. Progress in psychiatry (1). N Engl J Med 1993;329:552-560
9. Cohn JA, Alvares AP, Kappas A. On the occurrence of cytochrome P-450 and aryl hydrocarbon hydroxylase activity in rat brain. J Exp Med 1977;145:1607-1611
10. Guengerich FP, Mason PS. Immunological comparison of hepatic and extrahepatic cytochromes P-450. Mol Pharmacol 1979;15:154-164
11. Marietta MP, Vesell ES, Hartman RD, et al. Characterization of cytochrome P-450-dependent aminopyrine N-demethylase in rat brain: comparison with hepatic aminopyrine N-demethylation. J Pharmacol Exp Ther 1979;208:271-279
12. Fishman J, Norton BI, Krey L. 2-Hydroxylation of estrogens in the brain participates in the initiation of the preovulatory LH surge in the rat. Biochem Biophys Res Commun 1980;93:471-477
13. Walther B, Ghersi-Egea JF, Minn A, et al. Subcellular distribution of cytochrome P-450 in the brain. Brain Res 1986;375:338-344
14. Ghersi-Egea JF, Walther B, Minn A, et al. Quantitative measurement of cerebral cytochrome P-450 by second derivative spectrophotometry. J Neurosci Methods 1987;20:261-269
15. Bhagwat SV, Boyd MR, Ravindranath V. Rat brain cytochrome P450. Reassessment of monooxygenase activities and cytochrome P450 levels. Drug Metab Dispos 1995;23:651-654
16. Bhagwat SV, Boyd MR, Ravindranath V. Multiple forms of cytochrome P450 and associated monooxygenase activities in human brain mitochondria. Biochem Pharmacol 2000;59:573-582
17. Miksys S, Hoffmann E, Tyndale RF. Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 2000;59:1501-1511
18. Britto MR, Wedlund PJ. Cytochrome P-450 in the brain. Potential evolutionary and therapeutic relevance of localization of drug-metabolizing enzymes. Drug Metab Dispos 1992;20:446-450
19. Lavandera JV, Batlle AM, Buzaleh AM. Metabolization of porphyrinogenic agents in brain: involvement of the phase I drug metabolizing system. A comparative study in liver and kidney. Cell Mol Neurobiol 2007;27:717-729
20. Conroy JL, Fang C, Gu J, et al. Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat Neurosci 2010;13:284-286
21. Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738
22. Miksys SL, Tyndale RF. Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 2002;27:406-415
23. Bieche I, Narjoz C, Asselah T, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007;17:731-742
24. Nishimura M, Yaguti H, Yoshitsugu H, et al. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 2003;123:369-375
25. Howard LA, Miksys S, Hoffmann E, et al. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. Br J Pharmacol 2003;138:1376-1386
26. Miksys S, Tyndale RF. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 2004;36:313-333
27. el-Bacha RS, Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand) 1999;45:15-23
28. Granberg L, Ostergren A, Brandt I, et al. CYP1A1 and CYP1B1 in blood-brain interfaces: CYP1A1-dependent bioactivation of 7,12-dimethylbenz(a) anthracene in endothelial cells. Drug Metab Dispos 2003;31:259-265
29. Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 2001;11:1156-1166 (Pubitemid 32677289)
30. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58
31. Decleves X, Fajac A, Lehmann-Che J, et al. Molecular and functional MDR1-Pgp and MRPs expression in human glioblastoma multiforme cell lines. Int J Cancer 2002;98:173-180
32. Bendayan R, Ronaldson PT, Gingras D, et al. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. J Histochem Cytochem 2006;54:1159-1167
33. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162
34. Gazzin S, Strazielle N, Schmitt C, et al. Differential expression of the multidrug resistance-related proteins ABCb1 and ABCc1 between blood-brain interfaces. J Comp Neurol 2008;510:497-507
35. Nies AT, Jedlitschky G, Konig J, et al. Expression and immunolocalization of the multidrug resistance proteins, MRP1-MRP6 (ABCC1-ABCC6), in human brain. Neuroscience 2004;129:349-360
36. Cooray HC, Blackmore CG, Maskell L, et al. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002;13:2059-2063
37. Sisodiya SM, Martinian L, Scheffer GL, et al. Vascular colocalization of P-glycoprotein, multidrug-resistance associated protein 1, breast cancer resistance protein and major vault protein in human epileptogenic pathologies. Neuropathol Appl Neurobiol 2006;32:51-63
38. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-3464
39. Daood M, Tsai C, Ahdab-Barmada M, et al. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS. Neuropediatrics 2008;39:211-218
40. Dombrowski SM, Desai SY, Marroni M, et al. Overexpression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 2001;42:1501-1506
41. Zhang W, Mojsilovic-Petrovic J, Andrade MF, et al. The expression and functional characterization of ABCG2 in brain endothelial cells and vessels. FASEB J 2003;17:2085-2087
42. Eisenblatter T, Huwel S, Galla HJ. Characterisation of the brain multidrug resistance protein (BMDP/ABCG2/ BCRP) expressed at the blood-brain barrier. Brain Res 2003;971:221-231
43. Warren MS, Zerangue N, Woodford K, et al. Comparative gene expression profiles of ABC transporters in brain microvessel endothelial cells and brain in five species including human. Pharmacol Res 2009;59:404-413
44. Huang P, Rannug A, Ahlbom E, et al. Effect of 2,3,7,8-tetrachlorodibenzo- pdioxin on the expression of cytochrome P450 1A1, the aryl hydrocarbon receptor, and the aryl hydrocarbon receptor nuclear translocator in rat brain and pituitary. Toxicol Appl Pharmacol 2000;169:159-167
45. Iba MM, Storch A, Ghosal A, et al. Constitutive and inducible levels of CYP1A1 and CYP1A2 in rat cerebral cortex and cerebellum. Arch Toxicol 2003;77:547-554
46. Xu C, Li CY, Kong AN. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch Pharm Res 2005;28:249-268
47. Nishimura M, Naito S, Yokoi T. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab Pharmacokinet 2004;19:135-149
48. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470-477
49. Cordon-Cardo C, OBrien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-698
50. Akanuma S, Hori S, Ohtsuki S, et al. Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood-brain barrier. Neurochem Int 2008;52:669-674
51. Bauer B, Hartz AM, Fricker G, et al. Pregnane X receptor up-regulation of P-glycoprotein expression and transport function at the blood-brain barrier. Mol Pharmacol 2004;66:413-419
52. Dauchy S, Miller F, Couraud PO, et al. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 2009;77:897-909
53. Sasame HA, Ames MM, Nelson SD. Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. Biochem Biophys Res Commun 1977;78:919-926
54. Shafaati M, ODriscoll R, Bjorkhem I, et al. Transcriptional regulation of cholesterol 24-hydroxylase by histone deacetylase inhibitors. Biochem Biophys Res Commun 2009;378:689-694
55. Baker EK, El-Osta A. Epigenetic regulation of multidrug resistance 1 gene expression: profiling CpG methylation status using bisulphite sequencing. Methods Mol Biol 2010;596:183-198
56. Tyndale RF, Sunahara R, Inaba T, et al. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991;40:63-68
57. Tyndale RF, Li Y, Li NY, et al. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab Dispos 1999;27:924-930
58. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37
59. Chen ZR, Irvine RJ, Bochner F, et al. Morphine formation from codeine in rat brain: a possible mechanism of codeine analgesia. Life Sci 1990;46:1067-1074
60. Eckardt K, Li S, Ammon S, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998;76:27-33
61. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004;60:329-336
62. Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008;3:e1872
63. Klein C, Schlossmacher MG. The genetics of Parkinson disease: implications for neurological care. Nat Clin Pract Neurol 2006;2:136-146
64. Langston JW, Langston EB, Irwin I. MPTP-induced parkinsonism in human and non-human primates - clinical and experimental aspects. Acta Neurol Scand Suppl 1984;100:49-54
65. Brooks WJ, Jarvis MF, Wagner GC. Astrocytes as a primary locus for the conversion MPTP into MPP+. J Neural Transm 1989;76:1-12
66. Gilham DE, Cairns W, Paine MJ, et al. Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica 1997;27:111-125
67. Sams C, Mason HJ, Rawbone R. Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. Toxicol Lett 2000;116:217-221
68. Brown TP, Rumsby PC, Capleton AC, et al. Pesticides and Parkinsons disease - is there a link? Environ Health Perspect 2006;114:156-164
69. Tebourbi O, Driss MR, Sakly M, et al. Metabolism of DDT in different tissues of young rats. J Environ Sci Health B 2006;41:167-176
70. Corrigan FM, Wienburg CL, Shore RF, et al. Organochlorine insecticides in substantia nigra in Parkinsons disease. J Toxicol Environ Health A 2000;59:229-234
71. Kirby ML, Barlow RL, Bloomquist JR. Neurotoxicity of the organochlorine insecticide heptachlor to murine striatal dopaminergic pathways. Toxicol Sci 2001;61:100-106
72. Kitazawa M, Anantharam V, Kanthasamy AG. Dieldrin-induced oxidative stress and neurochemical changes contribute to apoptopic cell death in dopaminergic cells. Free Radic Biol Med 2001;31:1473-1485
73. Miller GW, Erickson JD, Perez JT, et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinsons disease. Exp Neurol 1999;156:138-148
74. Kanthasamy AG, Kitazawa M, Kanthasamy A, et al. Dieldrin-induced neurotoxicity: relevance to Parkinsons disease pathogenesis. Neurotoxicology 2005;26:701-719
75. Hatcher JM, Richardson JR, Guillot TS, et al. Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol 2007;204:619-630
76. Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69:169-174
77. Drozdzik M, Bialecka M, Mysliwiec K, et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinsons disease. Pharmacogenetics 2003;13:259-263
78. Lee CG, Tang K, Cheung YB, et al. MDR1, the blood-brain barrier transporter, is associated with Parkinsons disease in ethnic Chinese. J Med Genet 2004;41:e60
79. Westerlund M, Belin AC, Anvret A, et al. Association of a polymorphism in the ABCB1 gene with Parkinsons disease. Parkinsonism Relat Disord 2009;15:422-424
80. Zschiedrich K, Konig IR, Bruggemann N, et al. MDR1 variants and risk of Parkinson disease. Association with pesticide exposure? J Neurol 2009;256:115-120
81. Dutheil F, Beaune P, Tzourio C, et al. Interaction between ABCB1 and professional exposure to organochlorine insecticides in Parkinson disease. Arch Neurol 2010;67:739-745
82. Bartels AL, Kortekaas R, Bart J, et al. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging 2009;30:1818-1824
83. Selkoe DJ. Alzheimers disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis 2001;3:75-80
84. Weller RO, Nicoll JA. Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res 2003;25:611-616
85. Shibata M, Yamada S, Kumar SR, et al. Clearance of Alzheimers amyloid-ss (1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000;106:1489-1499
86. Deane R, Du Yan S, Submamaryan RK, et al. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003;9:907-913
87. Lam FC, Liu R, Lu P, et al. Beta-amyloid efflux mediated by p-glycoprotein. J Neurochem 2001;76:1121-1128
88. Kuhnke D, Jedlitschky G, Grube M, et al. MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimers amyloid-beta peptides - implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 2007;17:347-353
89. Cirrito JR, Deane R, Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 2005;115:3285-3290
90. Vogelgesang S, Cascorbi I, Schroeder E, et al. Deposition of Alzheimers beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics 2002;12:535-541
91. Vogelgesang S, Warzok RW, Cascorbi I, et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimers disease. Curr Alzheimer Res 2004;1:121-125
92. Xiong H, Callaghan D, Jones A, et al. ABCG2 is upregulated in Alzheimers brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides. J Neurosci 2009;29:5463-5475
93. Tai LM, Loughlin AJ, Male DK, et al. P-glycoprotein and breast cancer resistance protein restrict apical-to-basolateral permeability of human brain endothelium to amyloid-beta. J Cereb Blood Flow Metab 2009;29:1079-1083
94. Dutheil F, Beaune P, Loriot MA. Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 2008;90:426-436
95. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-236
96. Robey RW, To KK, Polgar O, et al. ABCG2: a perspective. Adv Drug Deliv Rev 2009;61:3-13
97. Shimada T, Fujii-Kuriyama Y. Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and 1B1. Cancer Sci 2004;95:1-6 (Pubitemid 38208399)
98. Vasiliou V, Gonzalez FJ. Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol 2008;48:333-358